Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.
The UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
Osaka Metropolitan University researchers analyzed the incidence in Japan of COVID-19-associated pulmonary aspergillosis ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback